Latest Share Consolidation News

Eden Innovations Ltd trimmed its loss to $5 million in FY2026 while erasing bank debt and converting loans into equity, supported by property sales and capital raises.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

Senetas Corporation reported a 4.7% rise in revenue to $20.2 million for FY2026, achieving a strong $4.4 million operating cash flow turnaround. The company advanced its AI governance platform while maintaining a robust sales pipeline and capital management strategy.

Adherium has tapped its major shareholder, Trudell Medical, for a further AUD 1 million unsecured loan to bolster working capital, adding to a recent USD 1.65 million facility.

Klevo Rewards extended its financial services footprint with two acquisitions and proposed a 10:1 share consolidation, while Fly Wallet posted $19 million revenue from an early-stage stablecoin trial in July 2026.

First Au Limited is seeking shareholder approval for a 20:1 share consolidation aimed at simplifying its capital structure and aligning its share price with the company’s development stage.

Celsius Resources (ASX:CLA) is set to consolidate its securities on a 1-for-20 basis, sharply reducing the number of shares, options, and warrants on issue while proportionally increasing exercise prices. The move follows a shareholder vote on cancelling a prior consolidation, with trading to resume under the new structure in September.

Enlitic slashed its net operating cash outflow by 76% in Q2 FY26 and secured binding commitments for a A$15 million conditional placement alongside convertible note conversions, positioning the company with a pro forma cash balance of about A$18 million and a debt-free balance sheet.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.